Repligen Corporation engages in the development and commercialization of bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, scale down validation of chromatography processes, and ELISA test kits. The company also provides filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Repligen Corporation

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Repligen (RGEN), Cardiff Oncology (CRDF) and Meiragt...

Analysts Offer Insights on Healthcare Companies: Repligen (RGEN), Cardiff Oncology (CRDF) and Meiragtx Holdings (MGTX)

Guggenheim analyst reiterated a Hold rating on Repligen yesterday. The company’s shares closed yesterday at $126.43. In addition to Guggenheim, Rep...

Guggenheim Reaffirms Their Hold Rating on Repligen (RGEN)

In a report released today, Daniel Arias from Stifel Nicolaus maintained a Buy rating on Repligen, with a price target of $207.00. Arias covers the...

Repligen (RGEN) Gets a Buy from Stifel Nicolaus

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Repligen (RGEN), Disc Medicine (IRON) and Cytokineti...

Analysts Offer Insights on Healthcare Companies: Repligen (RGEN), Disc Medicine (IRON) and Cytokinetics (CYTK)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on SOPHiA GENETICS (SOPH), CVRx (CVRX) and Repligen (RG...

Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Repligen (RGEN) and IQVIA Holdings (IQV) with bullis...

Current Quarter	$0.46	Next Quarter	$0.47
Current Year	$1.99	Next Year	$2.44
QoQ Growth	+2.2%	YoY Growth	+22.6%
3Y EPS CAGR	-36.2%	Target Price	$177.56
Consensus	Buy	Upside	+53.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RGEN	$116.07	+0.87%	339.61K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RGEN	$116.07	+0.9%	339.61K
3
4
5
6

RGEN

RGEN

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Repligen Corporation Data in Excel

Get Repligen Corporation Data in Excel